Skip to main content

Advertisement

SpringerLink
Log in

Stage-Specific Guided Adjuvant Treatment for Gastric Cancer

  • Gastrointestinal Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Coburn NG, Govindarajan A, Law CH, et al. Stage-specific effect of adjuvant therapy following gastric cancer resection: a population-based analysis of 4,041 patients. Ann Surg Oncol 2008; 15:500–7

    Article  PubMed  Google Scholar 

  2. Briasoulis E, Liakakos T, Dova L, et al. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 2006; 6:931–9

    Article  PubMed  Google Scholar 

  3. Roukos DH, Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 2002; 9:220–1

    PubMed  Google Scholar 

  4. Briasoulis E, Fatouros M, Roukos DH, Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 2007; 14:2691–5

    PubMed  Google Scholar 

  5. Roukos DH, Kappas AM, Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2005; 2:98–107

    Article  PubMed  Google Scholar 

  6. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357:1810–20

    Article  PubMed  CAS  Google Scholar 

  7. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355:11–20

    Article  PubMed  CAS  Google Scholar 

  8. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinomas of the stomach or gastroesophageal junction. N Engl J Med 2001; 345:725–30

    Article  PubMed  CAS  Google Scholar 

  9. Liakakos T, Roukos DH, More controversy than ever — challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol 2008; 15:956–60

    Article  PubMed  Google Scholar 

  10. Roukos DH, Kappas AM, Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 2002; 81:59–62

    Article  PubMed  Google Scholar 

  11. Kappas AM, Fatouros M, Roukos DH, Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 2004; 11:727–30

    Article  PubMed  Google Scholar 

  12. Roukos DH, Extended lymphadenectomy in gastric cancer: when, for whom and why. Ann R Coll Surg Engl 1998; 80:16–24

    PubMed  CAS  Google Scholar 

  13. Roukos DH, Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol 2000; 7:253–5

    Article  PubMed  CAS  Google Scholar 

  14. Roukos DH, Hottenrott C, Encke A, et al. Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 1994;3:115–25

    Article  PubMed  CAS  Google Scholar 

  15. Roukos DH, Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol 2004; 11:127–9

    Article  PubMed  Google Scholar 

  16. Roukos DH, Lorenz M, Encke A, Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery 1998;123:573–8

    Article  PubMed  CAS  Google Scholar 

  17. Roukos DH, Murray S, Briasoulis E, Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 2007;6:308–12

    Article  PubMed  CAS  Google Scholar 

  18. Roukos DH, Kappas AM, Tsianos E, Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 2002; 9:607–9

    Article  PubMed  Google Scholar 

  19. Norton JA, Ham CM, Van Dam J, et al. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 2007; 245:873–9

    Article  PubMed  Google Scholar 

  20. Roukos DH, Briasoulis E, Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 2007; 4:578–90

    Article  PubMed  CAS  Google Scholar 

  21. Roukos DH, Linking contralateral breast cancer with genetics. Radiother Oncol 2008; 86:139–41

    Article  PubMed  Google Scholar 

  22. Roukos DH, Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007; 357:1555–6; author reply 1556

    Article  PubMed  CAS  Google Scholar 

  23. Fatouros M, Baltoyiannis G, Roukos DH, The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 2008; 15:21–33

    Article  PubMed  Google Scholar 

  24. Roukos DH, Agnanti NJ, Paraskevaidis E, et al. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 2002; 9:941–3

    PubMed  Google Scholar 

  25. Agnantis NJ, Paraskevaidis E, Roukos D, Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 2004;11:1030–4

    Article  PubMed  Google Scholar 

  26. Roukos DH, Kappas AM, Agnantis NJ, Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 2003; 10:718–21

    Article  PubMed  Google Scholar 

  27. Fatouros M, Roukos DH, Arampatzis I, et al. Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 2005; 5:737–45

    Article  PubMed  Google Scholar 

  28. Roukos DH, HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2008; 358:197

    Article  PubMed  CAS  Google Scholar 

  29. Roukos DH, Breast-cancer stromal cells with TP53 mutations. N Engl J Med 2008; 358(15):1636

    PubMed  CAS  Google Scholar 

  30. Roukos DH, Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn 2008; 8:29–39

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 3rd Department of Surgery, Athens University, Athens, Greece

    T. Liakakos MD

  2. Department of Surgery, Ippokrateio Hospital University of Athens, Athens, Greece

    E. Fatourou MD

Authors
  1. T. Liakakos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Fatourou MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Liakakos MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liakakos, T., Fatourou, E. Stage-Specific Guided Adjuvant Treatment for Gastric Cancer. Ann Surg Oncol 15, 2622–2623 (2008). https://doi.org/10.1245/s10434-008-9913-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-008-9913-2

Keywords

Search

Navigation